Last reviewed · How we verify

NCT07176026

Follow-Up of Ureteral Stones ≤4 mm

ENROLLING BY INVITATION Last updated 16 September 2025
What this trial tests

trial in Kidney Stone in 1,600 participants. Enrolling by invitation.

Timeline
1 February 2025
Primary endpoint
1 January 2027
1 January 2027

Quick facts

Lead sponsorRegion Skane
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment1,600
Start date1 February 2025
Primary completion1 January 2027
Estimated completion1 January 2027
Sites2 locations across Sweden

Conditions studied

Sponsor

Region Skane — full company profile →

Who can join

18 and older, any sex, with Kidney Stone. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to evaluate the proportion of ureteral stones ≤4 mm that pass spontaneously within 4 and 8 weeks and assess if pain, blood test (S-creatinine), stone size, stone location and hydronephrosis can predict stone passage. The participants will be asked to fill in a questionare regarding symptoms, give a blood test and undergo a follow-up computed tomography.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Kidney Stone

Currently open trials in the same condition.

Other Region Skane trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07176026.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing